Comparing the multiple sources of cancer treatment data

Slides:



Advertisements
Similar presentations
Northern & Yorkshire Cancer Registry & Information Service NHS UKACR Conference 30 September How useful is the Cancer Waiting Times (CWT) dataset.
Advertisements

Tumour Matching N.Ireland Experience Colin Fox (IT Manager) Richard Middleton (Data Manager)
The LCA: Implementing a Quality Assurance and Informatics Strategy to Enhance Cancer Care Dr Shelley Dolan LCA Clinical Director.
Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.
West Midlands Cancer Intelligence Unit NHSBSP Surgical QA Data for the Year of Screening 1 April 2002 to 31 March 2003 Dr Gill Lawrence and Professor Jan.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
The Relationship of Surgeon and Hospital Volume with Long-Term Survival For Women with Breast Cancer Patrick J. Roohan New York State Department of Health.
Components of HIV/AIDS Case Surveillance: Case Report Forms and Sources.
National Cancer Intelligence Network data usage 17 November 2015 – Veronique Poirier – Principal Cancer Analyst – NCIN.
THE EFFECT OF AGE ON OUTCOME OF SYNOVIAL SARCOMA PATIENTS A DUTCH POPULATION BASED STUDY Myrella Vlenterie, SEJ Kaal, VKY Ho, R Vlenterie, WTA van der.
Carlos Rocha Registry Manager National Cancer Registration Service (South West) West Dean Registration Improvement of Non-Melanoma skin cancer.
How clinicians use data to make an impact on clinical outcomes Andrew Brodbelt Consultant Neurosurgeon and Clinical Director of Neurosurgery, The Walton.
Cancer Outcomes and Services Dataset What is COSD? Implications for Providers and Networks.
The Cancer Registry of Norway Jan F Nygård Head of the IT-department.
South West Public Health Observatory South West Regional Public Health Group Opportunities for future analysis by SWPHO Sean McPhail South West Public.
Routes to Diagnosis of Cancer in London, Katherine Henson, NCRAS, Presentation for London Public Health Knowledge and Intelligence Network.
Where can I find data on cancer? Victoria H Coupland London Knowledge and Intelligence Team 20 February 2014.
Enhancing Incidence Data with Passive End-Results Jill MacKinnon, Sarah Manson, and Mayra Alvarez Florida Cancer Data System.
South West Public Health Observatory South West Regional Public Health Group Overview of Neuro-oncology in the South West Sean McPhail South West Public.
Oesophago–Gastric Cancer Audit
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.
Improved survival in primary central nervous system lymphoma up to age 70: a population-based study on incidence, primary treatment and survival in the.
Oesophago–Gastric Cancer
Delivery of systemic therapy in Gloucestershire for NSCLC
National Oesophago–Gastric Cancer Audit 2015.
Stage I Non Small Cell Lung Cancer (NSCLC): single centre comparison of outcome by treatment with surgery, conventional radiotherapy and stereotactic ablative.
Colin Fischbacher Information Services Division (ISD)
The effect of neo-adjuvant chemotherapy on the discrepancy between the endoscopic ultrasonography (EUS) and pathological staging of oesophageal cancer.
Junliang Liu, M.D., M.Sc. Ph.D., FRCPC Assistant Professor
Segmented analysis of prostate cancer pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Oesophago–Gastric Cancer
Review of NLCA cases detected through non –COSD routes 2016
Treatment breakdown for prostate cancers
Treatment breakdown for breast cancers
Pathway for patients with suspected Breast Cancer
Treatment breakdown for NSCLC cancers
Six stage journey When diagnosed with a brain tumour.
Treatment breakdown for salivary gland cancers
National Lung Cancer Audit
S1316 analysis details Garnet Anderson Katie Arnold
Treatment breakdown for kidney cancers
Treatment breakdown for liver cancers
Treatment breakdown for larynx cancers
Frequently asked questions
Treatment breakdown for stomach cancers
Segmented analysis of the lung cancer median pathway from referral to treatment: This work was carried out in partnership between the Transforming.
Treatment breakdown for colon cancers
Treatment breakdown for oropharynx cancers
Treatment breakdown for bladder cancers
Treatment breakdown for oesophagus cancers
Pathway for patients with suspected Skin Cancer
Treatment breakdown for pancreatic cancers
Treatment breakdown for oral cavity cancers
Hannah Marder Cancer Manager UH Bristol
Treatment breakdown for uterine cancers
Principal recommendations
Treatment breakdown for rectum cancers
Treatment breakdown for SCLC cancers
Treatment breakdown for hypopharynx cancers
Treatment breakdown for cervical cancers
Treatment breakdown for ovary cancers
Treatment breakdown for other head and neck cancers
Treatment breakdown for vulva cancers
National Cancer Statistics in Korea, 2015
Pathway for patients with suspected HPB Cancer Inter Provider Transfer
2017 National Cancer Patient Experience Survey Overview of NBT Results Published September 2018 Carol Chapman Lead Cancer Nurse Patient Experience Group.
Pathway for patients with suspected Breast Cancer
Supporting precise data analysis without releasing patient records: the Simulacrum in action Cong Chen, Paul Clarke, Lora Frayling, Sally Vernon, Brian.
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Presentation transcript:

Comparing the multiple sources of cancer treatment data No acronym for the title yet Sean McPhail, Sam Johnson, Daniela Tataru, Margreet Lüchtenborg, Sally Vernon, Michael Peake (and thanks to James Thomas)

Background We are reasonably good at counting tumours, mortality, and calculating survival. Historically we have been less good at counting treatments. Is that still true? Comparing the multiple sources of cancer treatment data

Treatment Treatment Surgery Radiotherapy (RT) Chemotherapy (CT) Comparing the multiple sources of cancer treatment

5 Treatment data sources Inpatient Hospital Episode Statistics: HES Cancer Waiting Times: CWT Radio-therapy Data Set: RTDS Systematic Anti-Cancer Therapy: SACT Cancer Registration Comparing the multiple sources of cancer treatment data

Motivation Can we measure the fraction of patients are treated with each modality in each of these datasets? Are these sources consistent with one another? Can we use the most complete of these sources, or a combination, to assess the overall level of cancer treatment? Comparing the multiple sources of cancer treatment data

Methods Look at - Invasive tumours excluding non-melanoma skin Persons diagnosed 2012-10-01 to 2013-03-31 Treatment in -30 to +182 days of diagnosis Concentrate on – Fact of treatment Trust of first treatment Date of first treatment Comparing the multiple sources of cancer treatment data

The group of tumours under discussion 143,132 tumours in 6 months. 43,073 CTs. 30,927 RTs. Comparing the multiple sources of cancer treatment data

Linking these tumours to treatments Comparing the multiple sources of cancer treatment data

Fraction of tumours treated by CT and RT Registry CT: 24.8% RT: 18.3% Hospital Episode Statistics CT: 22.4% RT: 3.4% Cancer Waiting Times CT: 22.9% RT: 18.6% Systematic Anti-Cancer Therapy / RadioTherapy DataSet CT: 21.4% RT: 20.2% All of the above… CT: 30.1% (43,073) RT: 21.6% (30,927) Comparing the multiple sources of cancer treatment data

Dividing up a dataset with Venn Diagrams Of the people in this room how many have been to London and/or Dublin this year? London Dublin 30 20 20 Comparing the multiple sources of cancer treatment data

2-way and 3-way Venn Diagrams Comparing the multiple sources of cancer treatment data

Distribution of 43,073 chemotherapies HES CWT Registry SACT Comparing the multiple sources of cancer treatment data

Distribution of 43,073 chemotherapies HES CWT Registry SACT 3% 2% 1% 4% 1% 11% 4% 4% 4% 43% 4% 2% 10% 6% 1% Comparing the multiple sources of cancer treatment data

Are chemotherapy datasets consistent? Trust Matches Date Matches (exact) Results Implications Comparing the multiple sources of cancer treatment data

Are chemotherapy datasets consistent? Trust Matches Date Matches (30 day) Results Implications Comparing the multiple sources of cancer treatment data

Distribution of 30,927 Radiotherapies HES CWT Registry RTDS Comparing the multiple sources of cancer treatment data

Distribution of 30,927 Radiotherapies HES CWT Registry RTDS 1% 1% 0% 1% 11% 0% 1% 2% 5% 11% 1% 1% 61% 1% 3% Comparing the multiple sources of cancer treatment data

Are radiotherapy datasets consistent? Trust Matches Date Matches (exact) Results Implications Comparing the multiple sources of cancer treatment data

Are radiotherapy datasets consistent? Trust Matches Date Matches (30 day) Results Implications Comparing the multiple sources of cancer treatment data

The overall level of cancer treatment? If data sources were independent… … and capture of treatment data was also at random… … then flattening of cumulative completeness would imply complete data. But… registry feeds from CWT & HES systematic effects (e.g. private care, primary chemo, local issues, other reasons…) Comparing the multiple sources of cancer treatment data

But, what datasets do we believe? Combining all sources: CT: 30.1% RT: 21.6% Insist on dual source confirmation: CT: 26.4% RT: 19.7% Accept single source Registry, SACT/RTDS. Only accept HES with CWT: CT: 28.7% RT: 21.3% Lazy solution: Registry and SACT/RTDS only: CT: 28.2% RT: 21.3% Comparing the multiple sources of cancer treatment data

Summary Can we measure completeness in each? Yes Are they consistent? Yes Good agreement between both trust of diagnosis and treatment period (except RT for HES) – we appear to be matching clinical treatments. Can we define an overall cohort? Yes (-ish) CT nearly 30%, RT just over 20% We think we have eliminated much of the “random” missing data – “systematically” missing data may still be missing. Some clinical input and additional work to finalise definitions. Comparing the multiple sources of cancer treatment data

Thank you for listening! Background Methods Results Implications sean.mcphail@phe.gov.uk Comparing the multiple sources of cancer treatment